SUMMARY Ten patients with cirrhosis and portal hypertension received an initial 20 mg oral test dose of propranolol and subsequently 160 mg of a slow release preparation, orally, each day for seven days. Protein binding, serial plasma propranolol concentrations and effects on heart rate were studied. Protein binding was slightly reduced (mean 85%, range 78'9-88. 1%) compared with four normals (mean 87 9%). In patients with severe liver disease (serum albumin <30 g/l) propranolol remained detectable in plasma 24 hours after the single 20 mg dose and high steady state concentrations (mean 266 5 ng/ml, range 84-406) were observed during regular dosing. At steady state there was a significant correlation between log total plasma propranolol concentrations and the percentage fall in heart rate (r=0.659, p<0.05). We suggest that in patients with severe liver chronic disease (serum albumin <30 g/l), propranolol therapy should be initiated in hospital. The starting dose should be low (20 mg of the conventional formulation tds or 80 mg of the slow release preparation daily) and that regular monitoring of the heart rate should be carried out.
Propranolol has been shown to produce a sustained reduction in portal venous pressure in patients with cirrhosis and portal hypertension.' Furthermore, a controlled trial has shown that propranolol is an effective agent in the prevention of recurrent gastrointestinal haemorrhage in such patients.2 Although a recent report has failed to confirm this finding,3 other studies of propranolol in the management of recurrent variceal haemorrhage are being undertaken. In addition, many patients with cirrhosis and portal hypertension are receiving propranolol without being included in a clinical trial and they may be started on treatment outside hospital. In patients with chronic liver disease, the bioavailability, half-life and clearance of a drug may be altered. In addition, the unbound fraction may be increased so that its effects may be greater. 4 The pharmacological response to a drug such as propranolol may therefore be altered considerably in patients with cirrhosis and portal hypertension. The aim of this study was to investigate the pharmacology of propranolol in a group of patients with cirrhosis and portal hypertension who were likely to be offered this treatment. A slow release preparation of propranolol was chosen because once-daily dosing may increase the chances of compliance during long term therapy. This has potential benefits for patients with alcoholic cirrhosis and portal hypertension, and in those who are taking other medications.
Methods

PATIENTS
Ten patients with cirrhosis and portal hypertension were studied. Patients gave informed consent to the study, which had been approved by the local ethical committee. All (Table 2 ). After the administration of propranolol there was a reduction in heart rate to a mean of 64 beats/min, but there was little relationship between the absolute value of heart rate and log total plasma propranolol concentrations. In contrast, there was a significant correlation between the log total plasma propranolol concentration at steady state (beyond 72 hours on slow release propranolol) and the percentage fall in heart rate for each patient (r=0*659, p<005, n=10; Fig. 2 ). Patient no 10 showed a much greater response than the others for a concentration of around 100 ng/ml. Some of this difference could be accounted for on the basis of diminished plasma binding -21 1% free.
Discussion
Propranolol is a competitive antagonist at betaadrenoceptors, and its pharmacologic effects are therefore dose-related. Its effects in angina pectoris and cardiac arrhythmias are also dose and concentration related.7 8 Being basic and lipid-soluble, however, it is heavily bound to plasma proteins, particularly acid alpha-1-glycoprotein9 and albumin.10 It is the fraction which is free in plasma water that is pharmacologically (and therapeutically) active.
The pharmacokinetics1' of propranolol have been extensively studied in normal volunteers and in patients with a variety of disease states. In normal subjects, propranolol is almost completely absorbed after oral administration, but its bioavailability is low because of extensive presystemic metabolism by the liver.'2 13 Thus, after 20 mg by mouth, little or none of the drug can be detected in plasma. After reaching the circulation, the drug is removed at a rate which depends upon hepatic blood flow14 and the half-life is normally three to five hours after a single dose and slightly longer with repeated administration.'5 More recently, the pharmacokinetics of a slow release formulation of propranolol were studied in five normal volunteers.l Peak concentrations after eight days therapy reached 50 ng/ml, but values before the next dose fell to a trough of 17-5 ng/ml.
In the present study, the pharmacokinetics of propranolol in patients with cirrhosis and portal 17 -7- hypertension were grossly abnormal. After a test dose of 20 mg, much higher concentrations than normal were detectable, and in patients with severe liver damage propranolol could be detected 24 hours after the single dose. In addition, very high steady state concentrations were observed in this group after a regular once daily oral dose of 160 mg of the slow release preparation.
These values were associated with a considerable reduction (30% or greater) in heart rate at rest. The effects on heart rate were not only because of the higher total concentrations achieved but also because of an increased free fraction of the drug in plasma water. In a previous study of propranolol pharmacokinetics in patients with liver disease, after the intravenous administration of 40 mg (+)-propranolol, the most prominent abnormalities were found in patients in whom the serum albumin concentration was lower than 30 g/l. The half-life of propranolol was prolonged, distribution volume increased and clearance reduced in these patients. But clearance fell in proportion to that of indocyanine green, suggesting that hepatic blood flow was a limiting factor.17
In the present study we have confirmed previous observations that the greatest changes and highest total plasma propranolol concentrations occur in patients with serum albumin concentrations below 30 g/l, but our finding of high total plasma propranolol concentrations after oral dosing is new. Two explanations are theoretically possible; firstly, total concentrations may be raised by increased protein binding.18 This explanation can be discounted, as in the present study the binding of propranolol was slightly lower than normal. The alternative explanation is an increase in bioavailability because of diminished hepatic metabolism of the drug and/or shunting either within the liver or through porto-systemic anastomoses. It is not possible to state which of these latter possibilities is the more important.
Lebrec and colleagues2 first reported propranolol to be effective in the prevention of further gastrointestinal bleeding in patients with portal hypertension and well compensated liver disease (approx 85% of patients classified as Pugh/Child's grade A). Subsequently, there has been widespread use of propranolol in patients with portal hypertension, many of whom have decompensated cirrhosis ( We wish to thank Mrs B Gruchy for her skilled technical assistance, the British Heart Foundation for a grant towards the purchase of equipment used in this study, and Mrs I Strachan for typing the manuscript. 
